BioSpace News Archive

Hansa Biopharma announced that the Nomination Committee has been formed in accordance with the principles adopted by the Annual General Meeting on May 22, 2019 and has the following composition:

HART CADhs test addresses up to 30% of Emergency Department (ED) chest pain patients who cannot safely be ruled-in nor ruled-out for heart attack

Novel Drug Device Combination Product To Be Developed For The Treatment Of Suspected Acute Myocardial Infarction

Following the recent FDA clearance of its XACT Robotic System and the completion of its latest financial round totaling $36M, XACT Robotics™ Ltd. today announced the appointment of Brian L. Allen as Vice President of Sales and Marketing.

CRISPR Therapeutics (NASDAQ: CRSP) and Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced positive, interim data from the first two patients with severe hemoglobinopathies treated with the investigational CRISPR/Cas9 gene-editing therapy CTX001 in ongoing Phase 1/2 clinical trials.

Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of innovative technology which enables the functional selection of stem cells, today reported financial and operating results for the third quarter ended September 30, 2019 and provided a corporate update.

RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on commercialization and development of proprietary drugs for the treatment of gastrointestinal diseases, today reported its financial results and operational highlights for the third quarter ended September 30, 2019.

Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology therapeutics, today announced that Bill Newell, CEO of Sutro Biopharma, will present a corporate overview and business update at the Stifel 2019 Healthcare Conference on Wednesday

CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that the Company will present an overview of the company at the Three Part Advisors 2019 Southwest IDEAS Investor Conference on Wednesday, November 20, 2019

Novo Ventures and the Broad Institute of MIT and Harvard announced today the launch of the Novo Broad Greenhouse, a joint initiative to discover and propel transformative new therapies from academic science into the clinic.